NCT06495749Not yet recruiting
Early Diagnosis of Pancreatic Cancer Via Deciphering Multi-modal Immunological Signatures
Source: ClinicalTrials.gov · Last updated 16 Jul 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Prospective inclusion of 1000 patients with pancreatic cancer (early-stage pancreatic cancer accounts for approximately 75% of cases), 1000 patients with benign pancreatic diseases, and 1000 healthy individuals as controls. Peripheral blood samples were collected from newly diagnosed pancreatic cancer patients and healthy individuals. Using techniques such as plasma TCR/BCR-seq, CyTOF, and plasma proteomics, multi-modal individual immune characteristics were obtained and analyzed along with clinical information. An artificial intelligence predictive model was built based on these multi-modal individual immune characteristics to establish an early screening technique for pancreatic cancer. The sensitivity and specificity of this artificial intelligence model for early pancreatic cancer diagnosis were evaluated using an external multicenter sample test set.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 3000 (estimated)
- First submitted
- 23 Jun 2024
- Start date
- 1 Aug 2024
- Primary completion date
- 1 Jan 2027
- Lead sponsor
- Zhejiang University
- Diseases
- Pancreatic cancer, Childhood cancers
- NCT number
- NCT06495749
What you commit to
- Study type: Observational
- Planned participants: 3000
- From 1 Aug 2024 to the primary completion date, 1 Jan 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent immunodeficiency syndrome, active tuberculosis, HIV infection, etc.;
- Allogeneic transplantation requiring immunosuppressive therapy;
Other illness
- History of other malignancies;
Other
- Presence of organ dysfunction;
- Poor follow-up compliance.
Who the study is looking for
- Sign the informed consent form;
- Initial diagnosis as patients with pancreatic cancer, patients with benign pancreatic lesions, or healthy controls.
Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| First Affiliated Hospital, Medical College of Zhejiang University Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
| The first Affiliated Hospital, School of Medicine, Zhejiang University. Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.